This procedure alters the (generally) poor tumor immunogenicity into highly immunogenic material and creates neoepitopes that can be presented by DC to both CD4+ and CD8+ T cells and thereby break immune tolerance [179]. This evidence concerns the gene CD8A and neoplasm.